The Latest

RegenMed’s Investor VisionRegenMed is redefining how healthcare generates and uses real-worldevidence (RWE). Our patented Circles platform captures structured, verifiable, and clinically validated data from everyday medical practice — helping payers, providers, and researchers make smarter decisions.We recently launched our new Investor Page, highlighting the unique value propositions that make RegenMed a compelling early-stage investment opportunity.Where We Are Today‍Proven Platform: Circles is already enabling physician-owned datasets that are auditable, unbiased, and regulatorily compliant.‍Growing Traction: Adoption of Circles has accelerated since late 2024, with expanding interest from providers, researchers, and payers.‍Recurring Revenues: A SaaS-driven model with strong grossmargins and scalable network effects.Unlike traditional “big data” solutions, Circles datasets are transparent, clinically relevant, and FDA-fit for purpose.Where We’re GoingRegenMed is building the next layer of healthcare data intelligence:‍AI-Ready Infrastructure: Integrating a recursive AI learning layer that enables natural-language queries across Circles datasets — without the risks of opaque “black box” AI.‍Blockchain & Tokenization: Exploring models for secure, incentivized data ownership that empower both patients and providers.‍Global Growth: Scaling geographically and acrosstherapeutic areas to meet surging demand for trusted real-world evidence.Market OpportunityThe healthcare data opportunity is massive and expanding:‍Healthcare data analytics market: $64B, growing at 21% CAGR.‍Healthcare data market overall: $60B+, growing at 11% CAGR.‍Addressable opportunity for RegenMed: Exceeds $100B as demand for trusted RWE accelerates.This is a sector where quality, verifiable data is fast becoming the single most valuable resource for healthcare payers, regulators, researchers, and innovators.Competitive AdvantagesRegenMed is positioned uniquely because:We own the data — clear provenance and auditable origins.We deliver clinical-grade evidence aligned with FDA and payer standards.We offer low-burden deployment for physicians and patients.We’re already AI-ready — structured datasets support trustworthy insights.Investor Momentum‍Strong Investor Demand: Our last investment window closed ahead of schedule in March 2025.Proven Exits in the Space: Comparable firms such as CorEvitas were acquired for nearly $1B by Thermo Fisher.‍High Engagement: Regular investor webinars (Nov 2024, Dec2024, June 2025) outline both near-term execution and long-term scale.ConclusionRegenMed is a “Zero-to-One” company: defining a breakthrough category, delivering clinical and commercial value, and positioned in a rapidly expanding market.For investors seeking transformative healthcare opportunities, RegenMed offers a patented platform, growing traction, and a $100B+ addressable market — with the potential to reshape how medicine collects, validates, and applies real-world data.Explore more at invest.rgnmed.com.

Expanding Access to Bone-Preserving Bunion CareRegenMed is excited to announce our new client, HyperFlex Medical, creator of the HyperFlex® Bunion Correction System — a minimally invasive, bone-preserving implant designed to treat approximately 93% of bunion patients with mild-to-moderate hallux valgus. This approach allows same-day weight-bearing and faster recovery for patients.‍Note: HyperFlex brochure data.Unpacking the Market Growth and Patient Demand‍Global bunion treatment market was valued at around USD 1.47 billion in 2023, projected to reach USD 2.33 billion by 2032, with aCAGR of 6.8%.‍Bunion correction systems (including implants and related devices) generated roughly USD 730.4 million in 2022, forecast to reach USD 1.2 billion by 2030, at a 6.9% CAGR.‍Bunion surgery market alone stood at USD 437.8 million in 2023, expected to hit USD 606.1 million by 2029, growing at 5.7% CAGR.Regionally,US, EU4, UK, and Japan bunion market totaled USD 567.2 million in 2024, projected to rise to USD 1.02 billion by 2035, at 5.49% CAGR.‍(All projections based on industry market reports.)Size of the Patient Population & Clinical WorkforcePatients Suffering from Bunions‍About 23% of adults (18–65 years) have some degree of hallux valgus; the figure rises to 36% in individuals over 65 years.(EPRA Journals)Globally,the average prevalence of hallux valgus is around 19%, with variations by region andage.(BioMed Central, Wikipedia)In Western countries, it's estimated that as many as one-third of the population will develop bunions — especially common among women.(podiatryfaq.com)Physicians Treating BunionsThe American College of Foot and Ankle Surgeons (ACFAS) includes over 7,700 foot and ankle surgeons (podiatrists) in the U.S.(Wikipedia)The American Orthopaedic Footand Ankle Society (AOFAS) comprises around 2,400 orthopedic foot and ankle surgeons.(Wikipedia)Together, these two professional bodies represent more than 10,000 U.S. clinicians specializing in bunion and foot and ankle disorders.Why HyperFlex® Matters in This LandscapeWith up to 36% of older adults affected by bunions — and up to 19%globally — there’s a pressing need for effective, patient-friendly treatments. HyperFlex® answers this need:‍‍Minimally invasive: Small incision, no bone cutting, motion preservation.‍Fast recovery: Same-day walking, reduced healing times.‍Strong and reliable: Implant is 12× stronger than clinical load requirements.RegenMed’s Role and VisionBy partnering with HyperFlex Medical, RegenMed is aligning with its mission to deliver real-world, effective early interventions that improve outcomes and reduce the burden of more complex surgeries.Benefits include:‍Empowering clinicians to treat earlier, less invasively.Helping payers manage costs tied to surgical interventions.Providing patients with faster, more effective relief.

Investing in the Next Generation of Healthcare Technology InnovatorsRegenMed is proud to sponsor a University of Wisconsin–Madison Computer Sciences Capstone Project (CS 639, Fall 2025), joining the ranks of leading organizations such as Epic Systems, Capital One, American Family Insurance, Google, GE HealthCare, and Medtronic that have supported this nationally recognized program.The Capstone program pairs senior undergraduate students with industry partners on real-world software development projects, giving students a chance to tackle meaningful challenges while sponsors gain fresh insights, prototypes, and future talent pipelines. Since launching in 2021, the program has expanded to engage 100+ students and up to 18 sponsors each semester, ranging from Fortune 500 companies to startups and nonprofits.The RegenMed Project: Enhancing Patient-Reported OutcomesRegenMed’s sponsored project, titled “Electronic Patient Reported Outcomes (ePRO) Data Capture”, focuses on improving how patients share their post-treatment experiences.RegenMed’s platform already collects critical treatment information from both clinicians and patients. But one persistent challenge remains: patients often fail to complete outcome surveys in a timely manner. These surveys, known as ePROs, are vital to understanding treatment effectiveness and advancing value-based care.The Capstone team will explore ways to:Redesign the User Experience for patient-facing survey modules.Incorporate Gamification and Rewards to make survey completion more engaging.Develop Web and Mobile Enhancements using tools such as React JS, .NET C#, and AWS Cloud technologies (ECS, Lambda, Cognito, and more).By combining creativity with technical expertise, students will help RegenMed improve patient engagement, generating richer datasets for clinicians, payers, and researchers.Experienced Mentorship for Student SuccessCapstone students benefit from direct mentorship by RegenMed’s leadership and engineering team, including:Dolph Courchaine, RegenMed CIO, with over 40 years of experience in healthcare software engineering.Will Graupmann, RegenMed Software Engineer and UW–Madison alumnus, who brings recent student and startup perspectives.Laura Prey, RegenMed Board Member and IT executive, with more than three decades of experience in healthcare and insurance technology.This mentorship model ensures students learn not only advanced coding and cloud infrastructure, but also the real-world dynamics of healthcare data, insurance, and patient engagement.Why It Matters: Democratizing Healthcare EvidenceThe U.S. spends more than $5 trillion annually on healthcare, much of it on treatments with limited evidence of effectiveness. RegenMed’s mission is to democratize access to treatment-effectiveness data, empowering clinicians, patients, and payers to make better decisions.By sponsoring this project, RegenMed is helping to:Train the next generation of healthcare software engineers.Advance the science of real-world evidence (RWE) and patient engagement.Position Wisconsin students at the forefront of solving one of healthcare’s most pressing challenges.A Proud Tradition of Industry PartnershipsWith sponsors like Epic, GE HealthCare, Google, Amazon/Shopbop, Medtronic, and PBS Wisconsin contributing in past semesters, UW–Madison’s Capstone Program has become a launchpad for impactful collaborations between academia and industry. RegenMed is honored to join this tradition — and to contribute to the future of patient-centered healthcare innovation.

RegenMed and OREF Launch MOTIV™: A Peer-Reviewed Real-World Evidence Library for Musculoskeletal Innovation RegenMed, in partnership with the Orthopaedic Research and Education Foundation (OREF), has launched M.O.T.I.V.™ — a pioneering initiative to generate structured, peer-reviewed, and clinically meaningful real-world evidence (RWE) datasets across the full spectrum of musculoskeletal (MSK) conditions. MSK disorders represent one of the largest global health burdens. Nearly one-third of the world’s population will experience an MSK-related condition in their lifetime, from degenerative joint disease and traumatic injuries to bone cancers and rare genetic disorders such as osteogenesis imperfecta. In the United States alone, MSK care costs are estimated to exceed $980 billion annually, nearly 5% of U.S. GDP. Yet despite this immense cost, outcomes for patients remain inconsistent. Scientific progress is slowed by reliance on traditional clinical trials, which are lengthy, expensive, and selective. Meanwhile, insurers and government payers are placing new emphasis on outcomes tracking — such as Medicare’s penalties for providers who fail to collect long-term results on hip and knee replacements. The Limitations of Today’s Data While “real-world evidence” has become a buzzword in healthcare, the vast majority of available datasets are derived from electronic health records, insurance claims, or proprietary algorithms. These sources, though large, are fragmented, unverifiable, and often lack correlation between diagnosis, treatment protocols, and long-term outcomes. The result is evidence that fails to meet clinical utility standards, limiting its role in advancing precision care, improving health equity, or accelerating innovation. What Makes M.O.T.I.V.™ Different The M.O.T.I.V.™ (Musculoskeletal Outcomes Through Informed Validation) program is designed to overcome these barriers. Each dataset in the library is: • Peer-Reviewed by OREF: Every observational protocol is vetted by leading MSK researchers. • Anatomically & Clinically Specific: Defined by one anatomical region, one pathology, one treatment protocol, and one standardized outcomes assessment. • Validatable to Primary Sources: Built for transparency and trust, avoiding unverifiable big-data manipulation. • Longitudinal & Fit-for-Purpose: Meeting FDA requirements for clinical and regulatory use. • Statistically and Clinically Relevant: Designed to support meaningful insights that improve patient care. By setting a new standard for structured, verifiable real-world data, M.O.T.I.V.™ ensures that research and innovation in orthopaedics are both clinically rigorous and widely accessible. Driving Value-Based Care and Innovation The launch of M.O.T.I.V.™ marks a critical step toward achieving value-based care in musculoskeletal medicine. By creating datasets that are trusted, transparent, and clinically actionable, RegenMed and OREF are empowering: • Providers to benchmark treatments and improve patient outcomes. • Insurers and payers to make evidence-based reimbursement decisions. • Researchers to accelerate the path from lab to bedside. • Patients to benefit from more equitable, data-driven care. This initiative positions RegenMed and OREF at the forefront of a healthcare transformation — one where real-world evidence is no longer an aspiration, but a validated, practical tool for medical advancement

Join us for an exclusive RegenMed Circle Hour featuring our Physicians-Owned Circles focused on cutting-edge laser treatments for low back, shoulder, and knee conditions. Led by esteemed Principal Investigator Dr. Eric Broadworth, a Board-Certified Orthopaedic Clinical Specialist and founder of Fuel Physical Therapy & Sports Performance. When: Wednesday, 24 September Time: 1:45 PM EST Discover how Dr. Broadworth and his team harness real-world evidence collected in RegenMed Circles to drive better patient outcomes and advance evidence-based care in musculoskeletal health. Don’t miss this opportunity to learn from a leader in physical therapy innovation!